Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

20071,798 citationsJournal Articlebronze Open Access

Authors

Oliver A. Cornely · University of Cologne

Johan Maertens · Universitair Ziekenhuis Leuven

Drew J. Winston · University of California, Los Angeles

John R. Perfect · Duke Medical Center

Andrew J. Ullmann · Johannes Gutenberg University Mainz

Thomas J. Walsh · National Cancer Institute

David Helfgott

Abstract

In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival. There were more serious adverse events possibly or probably related to treatment in the posaconazole group. (ClinicalTrials.gov number, NCT00044486 [ClinicalTrials.gov].).

Topics & Keywords

Antifungal resistance and susceptibility Fungal Infections and Studies Neutropenia and Cancer Infections

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 356, Issue 4, pp. 348-359

DOI: 10.1056/nejmoa061094

Field-Weighted Citation Impact: 73.31